Roche at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Roche brings 3 presentations to ESGCT 2026 in Hamburg. Its contributions centre on controlling when a therapeutic gene is switched on, using an approved small molecule that acts through RNA splicing. A second strand retargets modified AAV capsids to cross the blood-brain barrier.
| Organization | ESGCT 2026 Attendance |
|---|---|
Roche Basel, Switzerland | |
Global pharmaceutical and diagnostics group whose gene therapy research includes AAV capsids that reach the brain and drug-controlled transgene switches. | Poster Wed Oct 28 1:30pm–3:30pm Tunable gene control via RNA splicing with a clinically approved small molecule Poster Thu Oct 29 2:00pm–4:00pm Inducible gene expression switch for precise therapeutic transgene control using a clinically approved small molecule Poster Thu Oct 29 2:00pm–4:00pm Retargeting Genetically Modified AAV Capsids to the Blood-Brain Barrier |
Instantly find 20 buyers from Roche
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction